Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenelzine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 2/20 | 1.00 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | IDO1 | P14902 | 2/20 | 1.00 |
| ▸ | KDM1A | O60341 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenelzine SCHEMBL3644150 | 1.00 | LMNA (1.00) | LMNACYP3A4SMN1; SMN2ALDH1A1IDO1 | |
| Phenelzine SCHEMBL6064850 | 0.97 | LMNA (0.95) | LMNACYP3A4SMN1; SMN2ALDH1A1IDO1 | |
| Phenelzine SCHEMBL118234 | 0.97 | CYP3A4 (0.95) | LMNACYP3A4SMN1; SMN2ALDH1A1IDO1 | |
| Phenelzine SCHEMBL2786042 | 0.97 | CYP3A4 (0.95) | LMNACYP3A4SMN1; SMN2ALDH1A1IDO1 | |
| Phenelzine SCHEMBL21084303 | 0.97 | LMNA (0.95) | LMNACYP3A4SMN1; SMN2ALDH1A1IDO1 | |
| Phenelzine SCHEMBL3602263 | 0.95 | LMNA (0.91) | LMNACYP3A4SMN1; SMN2ALDH1A1IDO1 | |
| Phenelzine SCHEMBL5072466 | 0.87 | LMNA (1.00) | LMNACYP3A4SMN1; SMN2ALDH1A1IDO1 | |
| Phenelzine SCHEMBL40652 | 0.87 | LMNA (1.00) | LMNACYP3A4SMN1; SMN2ALDH1A1IDO1 | |
| Phenelzine SCHEMBL3243562 | 0.87 | LMNA (1.00) | LMNACYP3A4SMN1; SMN2ALDH1A1IDO1 | |
| Phenelzine SCHEMBL27517877 | 0.85 | LMNA (0.96) | LMNACYP3A4SMN1; SMN2ALDH1A1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 20124 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-12544385-B2 | Combination drug therapies for CNS disorders | JAVED MOHAMMAD (US) | 2026-02-10 | — | — | US | claimed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H LUNDBECK AS (DK) | 2026-01-01 | — | — | US | claimed |
| WO-2025262247-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H. LUNDBECK A/S (DK) | 2025-12-26 | — | — | WO | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| US-4919916-A | Treatment of neurotransmitter-linked drug abuse | GOLWYN DANIEL H (US) | 1990-04-24 | — | — | US | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |
| US-4806667-A | Promoting production of useful livestock with silylated aminophenylethylamine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1989-02-21 | — | — | US | claimed |
| US-4786653-A | Treatment of neurotransmitter-linked drug abuse | GOLWYN DANIEL H (US) | 1988-11-22 | — | — | US | claimed |
| EP-0288867-A2 | Aminophenyl ethyl amine derivatives, process for their preparation and their use as performance promotors | BAYER AG (DE) | 1988-11-02 | — | — | EP | claimed |
| US-4758312-A | Adding colorless electrochemically active compound having positive reduction potential | NALCO CHEMICAL COMPANY (US) | 1988-07-19 | — | — | US | claimed |
| US-4670423-A | Monosilylated aminophenylethylamine derivatives, a process for their preparation, and their use for promoting growth | BAYER AKTIENGESELLSCHAFT (DE) | 1987-06-02 | — | — | US | claimed |
| EP-0089948-B1 | PHARMACEUTICAL COMPOSITIONS | COPPEN, Alec James (GB) | 1985-08-14 | — | — | EP | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |
| US-3993072-A | Microporous drug delivery device | ALZA CORPORATION (US) | 1976-11-23 | — | — | US | claimed |